Results 31 to 40 of about 7,663 (213)

Therapeutic environment for esketamine a policy [PDF]

, 2023
This project aimed to develop a structured policy surrounding the therapeutic environment of esketamine to provide continuity of care and maximize therapeutic benefits while mitigating possible side effects of esketamine. A literature review for the most
Stewart, Sierra
core   +1 more source

Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries

Middle East Current Psychiatry, 2023
Background There is a high unmet need among patients with treatment-resistant depression (TRD) as treatment with standard therapies is associated with low response and remission rates and high rates of relapse.
Nahida Nayaz Ahmed, Faisal Albishi, Suhail A. Khan, Ammar Alsayegh, Emmanuel Stip, Samer Makhoul   +5 more
doaj   +1 more source

Nowe leki w psychiatrii – kariprazyna, lurazydon, esketamina [PDF]

, 2021
Introduction: Invariably, the search for an “ideal drug” in psychiatry has been going for years, one that is safe and effective, prevents relapse and shows the least possible side effects.
Masiak, Jolanta, Masiak, Jolanta, Pożarowska, Kinga, Pożarowska, Kinga, Rudziński, Gracjan, Rudziński, Gracjan, Rusinek, Adam, Rusinek, Adam, Soroka, Ewelina, Soroka, Ewelina   +9 more
core   +2 more sources

Development and feasibility of a web application to monitor patients’ cancer-related pain [PDF]

, 2017
Background: In the outpatient setting, pain management is often inadequate in patients with cancer-related pain, because of patient- and professional-related barriers in communication and infrequent contacts.
Baan, M.A.G. (Mathilde), Oldenmenger, W.H. (Wendy), Rijt, C.C.D. (Carin) van der   +2 more
core   +1 more source

ESKALE study, a French real-world study describing TRD patients with Esketamine nasal spray: final analysis

European Psychiatry, 2023
Introduction Treatment resistant depression (TRD) affects a substantial proportion of patients with depression and carries a large unmet need. Esketamine nasal spray (NS), in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin ...
L. Samalin, L. Mekaoui, M. Rotharmel, P. de Maricourt, M.-A. Codet, E. Gaudre Wattinne   +5 more
doaj   +1 more source

Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression:A qualitative study [PDF]

, 2022
BACKGROUND: Ketamine and its enantiomer esketamine represent promising new treatments for treatment-resistant depression (TRD). Esketamine induces acute, transient psychoactive effects.
Breeksema, Joost J., Kamphuis, Jeanine, Kuin, Bouwe, Niemeijer, Alistair, Schimmel, Nina, Schoevers, Robert, van den Brink, Wim, Veraart, Jolien, Vermetten, Eric   +8 more
core   +2 more sources

A Clinical Rationale for Assessing the Impact of Childhood Sexual Abuse on Adjunctive Subcutaneous Esketamine for Treatment-Resistant Depression

Frontiers in Psychiatry, 2021
Background: A history of child sexual abuse (CSA) is related to higher suicide rates and poor treatment outcomes in depressed adult patients. Twenty years after the first study investigating the effects of ketamine/esketamine on depression and suicide ...
Eduardo Jorge Muniz Magalhães, Luciana Maria Sarin, Lorena Catarina Del Sant, Ana Cecília Lucchese, Carolina Nakahira, Marco Aurélio Tuena, Camila Brito Puertas, Victor Augusto Rodovalho Fava, Rodrigo Simonini Delfino, Rodrigo Simonini Delfino, Juliana Surjan, Juliana Surjan, Matheus Souza Steglich, Matheus Souza Steglich, Matheus Ghossain Barbosa, Guilherme Abdo, José Alberto Del Porto, José Alberto Del Porto, Charles B. Nemeroff, Hugo Cogo-Moreira, Hugo Cogo-Moreira, Acioly Luiz Tavares Lacerda, Acioly Luiz Tavares Lacerda, Acioly Luiz Tavares Lacerda, Acioly Luiz Tavares Lacerda, Andrea Feijo Mello, Andrea Feijo Mello   +26 more
doaj   +1 more source

Administration of Nebulized Ketamine for Managing Acute Pain in the Emergency Department: A Case Series [PDF]

, 2020
Ketamine administration in sub-dissociative doses in the emergency department (ED) results in effective pain relief in patients with acute traumatic and non-traumatic pain, chronic pain, and opioid-tolerant pain.
Butt, Mahlaqa, Drapkin, Jefferson, Hossain, Rukhsana, Likourezos, Antonios, Masoudi, Aidin, Motov, Sergey   +5 more
core  

Potential ‘anti-cancer’ effects of esketamine on proliferation, apoptosis, migration and invasion in esophageal squamous carcinoma cells

European Journal of Medical Research, 2023
Background Esketamine, an N-methyl-D-aspartate receptor antagonist, is commonly used for anesthesia and analgesia clinically. It was reported to negatively regulate cell proliferation, metastasis and apoptosis in cancer cells, including lung cancer and ...
Chao Li, Jingpu Shi, Sisi Wei, Huiqun Jia   +3 more
doaj   +1 more source

Efficacy and safety comparison of esketamine-propofol with nalbuphine-propofol for upper gastrointestinal endoscopy in children: a multi-center randomized controlled trial

Frontiers in Pediatrics, 2023
Background and AimsAnesthetics such as propofol, esketamine and nalbuphine are used during the upper gastrointestinal endoscopy to achieve and maintain the desired sedation level.
Xiaosu Zheng, Jinjin Huang, Sisi Wei, Yingying Tao, Yang Shen, Yanting Wang, Pan He, Mazhong Zhang, Ying Sun   +8 more
doaj   +1 more source